iShares Neuroscience and Healthcare ETF (IBRN)

NYSEARCA: IBRN · Real-Time Price · USD
29.02
-0.09 (-0.31%)
Oct 23, 2025, 4:00 PM EDT - Market closed
-0.31%
Assets$4.40M
Expense Ratio0.47%
PE Ratio16.48
Shares Out150,000
Dividend (ttm)$0.10
Dividend Yield0.35%
Ex-Dividend DateDec 17, 2024
Payout FrequencyAnnual
Payout Ratio5.73%
Volume876
Open29.07
Previous Close29.11
Day's Range29.02 - 29.13
52-Week Low17.86
52-Week High29.62
Beta0.73
Holdings70
Inception DateAug 24, 2022

About IBRN

Fund Home Page

The iShares Neuroscience and Healthcare ETF (IBRN) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market cap-weighted index that provides global equity exposure to companies that are positioned to benefit from neuroscience advancements. The index may hold securities from large- to small-cap. IBRN was launched on Aug 24, 2022 and is issued by BlackRock.

Asset Class Equity
Category Health
Region Global
Stock Exchange NYSEARCA
Ticker Symbol IBRN
ETF Provider BlackRock
Index Tracked NYSE FactSet Global Neuro Biopharma and MedTech Index

Top 10 Holdings

39.38% of assets
NameSymbolWeight
Praxis Precision Medicines, Inc.PRAX5.66%
PTC Therapeutics, Inc.PTCT4.10%
argenx SEARGX3.89%
Supernus Pharmaceuticals, Inc.SUPN3.85%
Xenon Pharmaceuticals Inc.XENE3.84%
Alkermes plcALKS3.67%
Axsome Therapeutics, Inc.AXSM3.67%
Biogen Inc.BIIB3.63%
Catalyst Pharmaceuticals, Inc.CPRX3.61%
Neurocrine Biosciences, Inc.NBIX3.46%
View More Holdings

Dividends

Ex-DividendAmountPay Date
Dec 17, 2024$0.10114Dec 20, 2024
Dec 20, 2023$0.0063Dec 27, 2023
Jun 7, 2023$0.00824Jun 13, 2023
Full Dividend History

Performance

IBRN had a total return of 7.12% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.61%.

News

Why Now Could Be The Time To Consider Neuroscience Investments

Recognition that aging populations will give rise to new healthcare needs and heightened awareness of mental health issues are bringing renewed focus to neurological health. Recent advances in genomic...

3 years ago - Seeking Alpha